首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1741127

Calcineurin抑制剂市场：按药物类型、按给药途径、按适应症、按分销管道、按最终用户、按地区

Calcineurin Inhibitor Market, By Drug Type, By Route of Administration, By Indication, By Distribution Channel, By End User, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

Calcineurin酶抑制剂市场规模预计在 2025 年为 123.7 亿美元，预计到 2032 年将达到 253.6 亿美元，2025 年至 2032 年的复合年增长率为 10.8%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	123.7亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	10.80%	2032年价值预测	253.6亿美元

Calcineurin抑制剂是一种免疫抑制剂。这些药物透过抑制免疫系统活动来防止免疫系统攻击移植器官。它们常用于器官移植，尤其是肾臟、心臟和肝臟移植。Calcineurin抑制剂主要有两种类型：Cyclosporine和Tacrolimus。这两种药物都已被证明能有效防止器官排斥，但也可能伴随严重的副作用，如肾臟损伤、高血压以及增加感染疾病和癌症的风险。由于器官移植和自体免疫疾病的日益流行，全球Calcineurin抑制剂市场预计将成长。新药的开发和现有药物适应症的扩大也在推动市场的发展。然而，这些药物的副作用和移植的高成本可能会阻碍市场的成长。全球Calcineurin抑制剂市场的主要企业是诺华公司、Astellas製药、艾尔建和辉瑞。这些公司专注于研发新型改良型Calcineurin酶抑制剂。按地区划分，北美占据钙Calcineurin抑制剂市场最大份额，其次是欧洲，原因是这些地区器官移植和自体免疫疾病的发生率较高。亚太地区市场预计将出现显着增长，这得益于该地区医疗支出的增加以及人们对器官移植的认识不断提高。

市场动态：

预计在不久的将来，自体免疫疾病和器官移植病例的增加将推动全球Calcineurin抑制剂市场的成长。用于预防移植器官排斥反应的Calcineurin抑制剂需求的不断增长是主要驱动因素。Tacrolimus是一种Calcineurin抑制剂，一种用于治疗器官移植患者的免疫抑制剂，可降低人体对移植器官的排斥能力。

然而，Calcineurin抑制剂的副作用，例如皮肤刺激和胃肠道疾病，可能会阻碍市场的成长。此外，口服药物过量相关的风险，例如肾毒性和肝毒性，预计也将在不久的将来阻碍市场的成长。

本研究的主要特点

本报告对全球Calcineurin抑制剂市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球Calcineurin酶抑制剂市场的主要企业概况。
本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球Calcineurin酶抑制剂市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
可以透过用于分析全球Calcineurin酶抑制剂市场的各种策略矩阵来促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 12.37 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.80%	2032 Value Projection:	USD 25.36 Bn

Calcineurin inhibitors are a type of immunosuppressant. These drugs work by suppressing the activity of the immune system to prevent it from attacking the transplanted organ. They are commonly used in organ transplantation, especially kidney, heart, and liver transplants. There are two main types of calcineurin inhibitors: cyclosporine and tacrolimus. Both of these drugs have been proven to be effective in preventing organ rejection, but they can also have serious side effects, including kidney damage, high blood pressure, and an increased risk of infections and cancer. The global calcineurin inhibitors market is expected to grow due to the increasing prevalence of organ transplantation and autoimmune diseases. The market is also driven by the development of new drugs and the expansion of indications for existing drugs. However, the market growth may be hindered by the side effects of these drugs and the high cost of transplantation. Key players in the global calcineurin inhibitors market include Novartis AG, Astellas Pharma Inc., Allergan, Inc., and Pfizer Inc. These companies are focusing on research and development activities to develop new and improved calcineurin inhibitors. In terms of geography, North America holds the largest share of the calcineurin inhibitors market, followed by Europe. This is due to the high prevalence of organ transplantation and autoimmune diseases in these regions. The market in Asia Pacific is expected to grow at a significant rate due to the increasing healthcare expenditure and the growing awareness about organ transplantation in this region.

Market Dynamics:

Increasing cases of autoimmune diseases and organ transplantation is expected to drive growth of the global calcineurin inhibitor market in the near future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body's ability to reject a transplanted organ.

However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to hamper the market growth in the near future.

Key features of the study:

This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcineurin inhibitor market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market

Detailed Segmentation:

Global Calcineurin Inhibitor Market, By Drug Type:
- Cyclosporine
- Tacrolimus
- Pimecrolimus
- Voclosporin
- Others
Global Calcineurin Inhibitor Market, By Route of Administration:
- Oral
- Topical
- Intravenous
Global Calcineurin Inhibitor Market, By Indication:
- Organ Transplant Rejection Prevention
- Autoimmune Diseases
- Ophthalmic Diseases
- Other Dermatological Conditions
Global Calcineurin Inhibitor Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Calcineurin Inhibitor Market, By End User:
- Hospitals
- Specialty Clinics
- Dermatology Centers
- Transplant Centers
Global Calcineurin Inhibitor Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Novartis AG
- Amgen
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Incyte Corporation
- Chiesi Farmaceutici S.p.A.
- Astellas Pharma Inc.
- Sanofi SA
- Bristol Myers Squibb Company
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd.
- Senju Pharmaceutical Co. Ltd
- Abbott
- Lupin Limited
- Vibcare Pharma Pvt. Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Calcineurin Inhibitor, By Drug Type
- Market Calcineurin Inhibitor, By Route of Administration
- Market Calcineurin Inhibitor, By Indication
- Market Calcineurin Inhibitor, By Distribution Channel
- Market Calcineurin Inhibitor, By End User
- Market Calcineurin Inhibitor, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Calcineurin Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Calcineurin Inhibitor Market, By Drug Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2025 - 2032
- Segment Trends
Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Pimecrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Voclosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Calcineurin Inhibitor Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Calcineurin Inhibitor Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Organ Transplant Rejection Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Other Dermatological Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Calcineurin Inhibitor Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Calcineurin Inhibitor Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Dermatology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Transplant Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

10. Global Calcineurin Inhibitor Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Chiesi Farmaceutici S.p.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Senju Pharmaceutical Co. Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vibcare Pharma Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

12. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Calcineurin抑制剂市场：按药物类型、按给药途径、按适应症、按分销管道、按最终用户、按地区